head shot image

Ron Burnette, PharmD, PhD


No longer accepting new graduate students.

Our research currently focuses on two areas:

At the whole organism level (animal and human), our research group is interested in developing computer algorithms, using the principles obtained from pharmacokinetics, pharmacodynamics and pharmacogenomics, in order to optimize drug delivery and to understand drug interactions.

At the molecular level, the basic premise underlying our research is that one can combine experimental data, such as that obtained from spectroscopic techniques and X-ray crystallography, in a synergistic manner with computational chemistry to determine molecular structure and to understand intermolecular and intramolecular interactions. This, in turn, provides the basis for beginning to understand drug delivery systems at a more fundamental level. More precisely these investigations provide a mechanism by which one can start to predict how specific molecular changes will alter a drug delivery system at both the structural and energetic level.

Ron received his B.S. degree (1971) in electrical engineering from the University of California-Irvine, M.S. degree (1973) in electrical engineering from Stanford University, and Pharm.D. (1979) and Ph.D. (1982) degrees in pharmaceutical chemistry from the University of California-San Francisco. He joined the Wisconsin faculty in 1982.

Professional Interests: Computer algorithm development involving pharmacokinetics, pharmacodynamics and pharmacogenomics. Molecular level understanding of drug carrier interactions through the use of high resolution NMR, X-ray crystallography and computational chemistry.


  • BS 1971 Electrical Engineer - University of California-Irvine
  • MS 1973 Electrical Engineer - Stanford University
  • PharmD 1979 Pharmacy - University of California-San Francisco
  • PhD 1982 Pharmaceutical Chem. - University of California-San Francisco
Highlighted Publications:
  • Zhang, RR, Grudziinski, JJ, Mehta, TI, Burnette, RR et al. In Silico Docking of Alkylphosphocholine Analogs to Human serum Albumion Predicts Partitioning and Pharmacokinetics., Mol. Pharmaceutics 2019, 16, 3350-3360.
  • Grudzinski JJ, Floberg JM, Mudd SR, … Burnette, RR, et al. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT. Phys. Med. Biol. Mar 2012;57(6):1641-1657.
  • Shrestha HK, Beg MA, Burnette RR, Ginther OJ. Plasma Clearance and Half-Life of Prostaglandin F2alpha: A Comparison Between Mares and Heifers. Biol. Reprod. Jul 2012;87(1).
  • Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape. Grudzinski JJ, Burnette RR, Weichert JP, Jeraj R. Cancer Biother Radiopharm. (2010) 25(4):417-26.
  • Tris(1,4,7,10-tetraoxacyclododecane)-di-lithium diperchlorate I.A. Guzei, L.C. Spencer, L. Xiao and R.R. Burnette Acta Crystallographica Section E66(4) m438-m439. (2010).
  • 1,4,7,10-tetraoxacyclododecane-trideuteroacetonitrile-lithium perchlorate I.A. Guzei, L.C. Spencer, L. Xiao and R.R. Burnette Acta Crystallographica Section E66(4) m440-m441. (2010).
  • Guzei, I. A., Su, J. W., Spencer, L. C., Burnette, R. R. (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane)sodium perchlorate. Acta Crystallogr., Sect. E Struct. Rep. Online, E65(11), m1381-m1382, (2009).
  • Su, Joe and Burnette, Ronald. Investigation of Noncovalent Complexation with Hartree-Fock, Density Functional Theory, and Natural Bond Orbital Methods: a 222 Cryptand-Ion Binding Selectivity Study. ChemPhysChem (A European Journal of Chemical Physics and Physical Chemistry) Vol. 9, 1989-1996, (2008).
  • R.R. Burnette, F. Weinhold, "Determination of the Conformation of 2-Hydroxy- and 2-Aminobenzoic Acid Dimers Using 13C NMR and Density Functional Theory/Natural Bond Order Analysis: The Central Importance of the Carboxyilic Acid Carbon" Journal of Physical Chemistry A,110 (28); 8832-8839 (2006).
  • R. R. Burnette and K. A. Connors, "Statistical Properties of Thermodynamic Quantities for Cyclodextrin Complex Formation" Journal of Pharmaceutical Sciences 89:11, 1389 - 1394 (2000).
  • R.R. Burnette, "Pharmacokinetics and Dynamics of Temporal Delivery," in Electronically Controlled Drug Delivery, B. Berner and S.M. Dinh (eds.), CRC Press, Boca Raton, 93-109, 1998.
  • R.R. Burnette, "Computer Simulation of Human Blood Flow and Vascular Resistance," Computers in Biology and Medicine, 265: 363-369 (1996).
  • Burnette, R. R. 1992. Fundamental pharmacokinetic limits on the utility of using a sinusoidal drug delivery system to enhance therapy. Journal of Pharmacokinetics and Biopharmaceutics, 20 (5): 477-500.